In vivo assembly of nanoparticle components to improve targeted cancer imaging.
Ontology highlight
ABSTRACT: Many small molecular anticancer agents are often ineffective at detecting or treating cancer due to their poor pharmacokinetics. Using nanoparticles as carriers can improve this because their large size reduces clearance and improves retention within tumors, but it also slows their rate of transfer from circulation into the tumor interstitium. Here, we demonstrate an alternative strategy whereby a molecular contrast agent and engineered nanoparticle undergo in vivo molecular assembly within tumors, combining the rapid influx of the smaller and high retention of the larger component. This strategy provided rapid tumor accumulation of a fluorescent contrast agent, 16- and 8-fold faster than fluorescently labeled macromolecule or nanoparticle controls achieved. Diagnostic sensitivity was 3.0
SUBMITTER: Perrault SD
PROVIDER: S-EPMC2895069 | biostudies-literature | 2010 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA